Pharmacokinetics and Mechanism of Action
In clinical pharmacology, propanidid (Propanididum) holds a unique position due to its kinetic properties. The drug is available as an oily liquid packaged in ampoules for intravenous administration.
A key feature of the drug is its ultra-short duration of action. Following intravenous injection, the effect develops almost instantly, with the onset of action occurring within 20–40 seconds. Induction of anesthesia is smooth, completely omitting the excitation phase characteristic of many classical anesthetics.
The total duration of the surgical stage is only 3–4 minutes. This phenomenally short period of activity is due to its specific biotransformation mechanism. Unlike drugs metabolized by hepatic enzymes (such as monoamine oxidases or pseudocholinesterases), propanidid undergoes rapid hydrolysis directly within the bloodstream. The primary catalyst for this process is plasma cholinesterase, which rapidly cleaves the molecule, terminating its action.
Indications
The specific pharmacological profile of the drug defines a narrow yet highly demanded range of indications:
- Induction of anesthesia. The drug is ideal for initiating general anesthesia, ensuring rapid loss of consciousness without psychomotor agitation before transitioning to maintenance anesthesia.
- Short procedures. A duration of 3–4 minutes is sufficient for quick interventions such as biopsies, reduction of traumatic dislocations, and tooth extraction.
- Ambulatory practice. Due to rapid plasma hydrolysis, patients recover swiftly. Clear consciousness returns within 2–3 minutes after the end of the drug's effect, and complete recovery of psychomotor functions takes no longer than 20–30 minutes, which is critical for outpatient surgery.
Side Effects and Complications
Administration of propanidid requires careful monitoring due to the risk of adverse reactions:
- Respiratory system: The response is biphasic. Initially, transient hyperventilation occurs, which is sharply followed by respiratory depression—potentially leading to apnea lasting 10 to 30 seconds.
- Cardiovascular system: Hemodynamic shifts may occur, manifesting as tachycardia (increased heart rate) and decreased blood pressure.
- Neurological status: Brief involuntary muscle twitching may be observed during the early stage of anesthesia.
- Local and allergic reactions: The drug irritates the vascular wall, causing pain along the vein during injection. There is also an increased risk of hypersensitivity reactions.